ClinicalTrials.gg
RecruitingNCT06510543GENTLEMANUpdated Jul 19, 2024

Goal-directed Enteral Nutritional Perioperative Management

An interventional study of Goal-directed EN therapy and Conventional EN therapy in Esophagus Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 17 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Esophageal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 17 open to participants now, 17 under way, 4 of them phase 3. Esophageal Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Planned enrollment
5th of 21
400 · median 120
Started
2024
with 4 others
No phase
7 of 22
4 open now
Primary completion
2026-08
later than 9 of 16 live
Registered
19th of 22
by date

Among the 22 studies in Esophageal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2024, is one of 7 with no phase, reaches primary completion later than 9 of the 16 other live ones, and was the 19th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

17 of the 22 studies in Esophageal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Esophageal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, or all of them as a file.
02

Study summary

This clinical trial aims to determine whether perioperative goal-directed nutritional therapy can prevent postoperative pulmonary and other major complications in malnourished esophageal squamous cell cancer patients. Its main question is whether individualized nutritional therapy can improve short-term surgical outcomes and long-term prognosis. Researchers will compare goal-directed and conventional nutritional therapy to identify differences in morbidities and survival.

Read the detailed description

Severe malnutrition is a significant risk factor for postoperative complications in esophageal cancer patients. Early oral nutritional supplementation after surgery can prevent weight loss and improve quality of life. The EFFORT trial showed that individual-based enteral nutrition support reduced complications, extended 1-year survival, and improved quality of life. This study aims to assess the safety and effectiveness of individualized perioperative nutrition support guided by daily energy targets in esophageal cancer patients at nutritional risk. It also seeks to determine if supplementing immunonutrition can effectively reduce postoperative complications. This study was conducted as a multicenter, open-label, randomized, controlled phase 3 trial. The experiment group was administered goal-directed enteral nutritional therapy, while the control group received conventional enteral nutritional therapy. The study observed the participants' major pulmonary and other complications within 90 days post-surgery and nutritional status, disease-free survival (DFS), and overall survival (OS) in both groups.

03

Conditions studied

  • Esophagus Cancer

Keywords

  • Esophageal Cancer
  • Esophagectomy
  • Nutritional Therapy
  • Morbidity
  • Survival
  • Malnourished
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-80 years old;
  2. PS 0\~1;
  3. NRS 2002 score ≥3;
  4. Malnutrition diagnosed according to the GLIM criteria;
  5. Histopathologically confirmed as esophageal squamous cell carcinoma;
  6. Primary tumors located in thoracic esophagus;
  7. Resectable locally advanced disease with clinical stage II to IVA (8th edition UICC/AJCC) evaluated by a multidisciplinary team;
  8. therapy will be administered, which may entail preoperative chemo-radiotherapy, chemotherapy only, or a combination of immunotherapy such as /PD-L1;
  9. for random assignment and completion of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. NRS 2002 score \< 3;
  2. Upfront surgery without treatment;
  3. Any comorbidity interferes with the digestion and absorption of ORAL IMPACT®;
  4. Receiving any other nutritional support during the study;
  5. Unable to consume nutrition orally or receive it through tube feeding before surgery;
  6. History of other in the past 5 years, except successfully treated basal-cell skin carcinoma and cervical tumors in situ;
  7. Severe abnormalities of liver and kidney functions (≥2 times the ; Total Tbil≥2 upper limit of normal; Creatinine Cr≥2 upper limit of normal);
  8. Metabolic disorders, including uncontrolled diabetes mellitus or fasting blood glucose ≥10mmol/L, hypothyroidism, or hyperthyroidism;
  9. Receiving fat emulsion containing Omega-3 fatty acids, glutamine, thymosin, , thyroxine, growth hormone, and anti-tumor necrosis factor biologic agents
  10. History of known allergy to any component of ORAL IMPACT®;
  11. Pregnant or lactating women, women of with either a positive pregnancy test at baseline or not using a reliable and appropriate method;
  12. Refuse to sign the consent or unable to follow the study protocol;
  13. Inappropriate to participate in this study judged by investigators.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Goal-directed enteral nutritional therapy

    The participants will be administered a supervised goal-directed nutritional therapy. The enteral nutrition (EN) regimens include homemade meals with or without ORAL IMPACT® according to the daily goal.

    Dietary Supplement: Goal-directed EN therapy

  • Active comparator
    Conventional enteral nutritional therapy

    The participants will be administered with an unsupervised and liberal nutritional support. The EN regimens will not include ORAL IMPACT®.

    Dietary Supplement: Conventional EN therapy

Interventions

  • Dietary supplementGoal-directed EN therapy

    The participants will be administered a supervised goal-directed nutritional therapy. The enteral nutrition (EN) regimens include homemade meals with or without ORAL IMPACT® according to the daily goal.

  • Dietary supplementConventional EN therapy

    The participants will be administered the conventional nutritional therapy according to the Chinese expert consensus on perioperative nutritional support in enhanced recovery after surgery (2019 edition).

06

What researchers measure

Primary outcomes

  1. Rate of postoperative pulmonary complications

    According to the Esophagectomy Complications Consensus Group (ECCG) standardization of complications reporting, pulmonary complications include pneumonia, pleural effusion, pneumothorax, atelectasis, mucous plugging, respiratory failure, acute respiratory distress syndrome, acute aspiration, tracheobronchial injury, and prolonged air-leak.

    Time frame: Randomization to three months after surgery

  2. Rate of unplanned hospital admissions

    Any admission (all cause) for an unforeseen or unplanned (non-elective) cause within 90 days of discharge from an index acute hospital admission.

    Time frame: Randomization to three months after surgery

  3. Rate of unplanned ICU admission

    Any admission (all cause) for an unforeseen or unplanned (non-elective) cause within 90 days of discharge from an index acute ICU admission.

    Time frame: Randomization to three months after surgery

  4. Overall survival

    The time from randomization to death. Any patients lost to follow up or still alive at the time of evaluation are censored.

    Time frame: Randomization to five years

Secondary outcomes

  1. Rate of postoperative non-pulmonary complications

    Non-pulmonary complications according to the ECCG standardization of complications reporting.

    Time frame: Randomization to three months after surgery

  2. Level of serum prealbumin

    Prealbumin, also known as transthyretin, has a half-life in plasma of ∼2 days, much shorter than that of albumin. Prealbumin is therefore more sensitive to changes in protein-energy status than albumin, and its concentration closely reflects recent dietary intake rather than overall nutritional status.

    Time frame: Randomization to three months after surgery

  3. Body mass index (BMI)

    A person's weight in kilograms divided by the square of height in meters.

    Time frame: Randomization to three months after surgery

  4. Lean body mass

    The weight of the body minus the⁣ fat content, representing the amount of⁣ muscle, bone, and organs in the body.

    Time frame: Randomization to three months after surgery

  5. Rate of treatment-related adverse events (TRAEs)

    An event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state.

    Time frame: Randomization to three months after surgery

  6. Rate of R0 resection

    Distance between tumor and the circumferential resection margin (CRM) more than 1 mm.

    Time frame: Randomization to three months after surgery

  7. Rate of pathologic complete response (pCR)

    The absence of invasive/in situ cancer in the resected esophagus and regional lymph nodes.

    Time frame: Randomization to three months after surgery

  8. Disease-free survival (DFS)

    Defined as the proportion of patients without disease progression or death.

    Time frame: Randomization to five years

  9. Scale of health-related quality of life (HRQOL)

    A state of complete physical, mental and social well-being, and not merely the absence of disease and infirmity evaluated by EORTC OES18、EQ-5D、FAACT.

    Time frame: Randomization to three months after surgery

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Aug 2026, 29 months after the start.

Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 29 months is below that.

Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Jul 19, 2024
StartActual
Mar 30, 2024
Primary completionEst.
Aug 30, 2026
CompletionEst.
May 30, 2031
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06510543
Responsible party
YIN LI (Principal Investigator, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Jul 19, 2024
Start date
Mar 30, 2024
Primary completion
Aug 30, 2026 (estimated)
Completion
May 30, 2031 (estimated)
Last update
Jul 19, 2024

Study contacts

Xiaozheng Kang, M.D.
Contact
kangxz@cicams.ac.cn
+86 13910052790
Yin Li, M.D.
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion